Variceal Bleeding

Active Gastroesophageal Varices bleeding

 

Background: 

Gastroesophageal varices bleeding is associated with a mortality rate approaching 20-30%.  

Bleeding from varices stops spontaneously only in 50% of patients



Evaluation: 

History: 

Prior complications, medications, fever, abdominal/chest pain, vomiting, melena, syncope/pre-syncope, hematemesis, cause of cirrhosis, prior interventions on varices, weights.

Exam: 

Evaluate hemodynamic status immediately (consider use of beta blockers). 

Look for signs of chronic liver disease – spider angiomata, palmar erythema, jaundice, ascites (shifting dullness, fluid wave, etc.), coagulopathy (petechiae, purpura), ENT exam (pharynx), CV, pulmonary, extremities, mental status.

Labs

ECG, CBC, coags, renal function, VBG/lactate, Ammonia level, electrolytes, LFTs, type and cross, fibrinogen, CXR and EKG 




Management: 

First obtain bilateral IV access (large bore advised), monitors, supplemental oxygen. Wear personal protective equipment. 

 

Airway: 

This is one of the most difficult airways to management due to shock state, difficulty with visualization, rapid desaturation with sedative/paralytic, and extensive blood loss.

Use NG tube to decompress stomach (remove the ticking time bomb). 

May use metoclopramide 10 mg or erythromycin 250 mg IV to assist in moving blood through GI tract

Place in Trendelenberg if vomiting (keep blood out of lungs).




Bleeding and Circulation:

Hemostatic Resuscitation: Do not rely on PT/PTT/INR to assess coagulation status. Consider use of TEG instead. May need to start MTP

Consider pRBCs if Hb <7 g/dL (goal of Hb between ≥7 g/dL (70 g/L) and <9 g/dL). If pt received >6 units of pRBCs in <3 hours check serum ionized calcium concentration (due to citrate binding of ionized calcium) 

Platelets – if initial platelet count is < 50,000/microL 

Prohemostatic products – consider fresh frozen plasma, PCC on case by case basis, cryoprecipitate targeting fibrinogen 150-200 mg/dL. Consider to use TXA 1g IV. 



Target resuscitation end points of mentation, capillary refill, MAP, urine output. 




Source Control: Emergency GI and IR consults. 

May use erythromycin or metoclopramide to improve view for EGD. 

Use octreotide 50 mcg IV bolus, 50 mcg/hr IV infusion (or vasopressin with nitroglycerin), which is associated with decreased products transfused. 



Be ready with other devices: Sengstaken-Blakemore, Minnesota, Linton-Nachlas tubes.

https://www.youtube.com/watch?v=Yv4muh0hX7Y



Screen Shot 2019-08-12 at 3.40.57 PM.png


Prevent and Treat Complications

Infection associated with 25-65% of upper GI bleeds from varices (UTI, SBP, pneumonia):

Ceftriaxone 1 g IV or cefotaxime 2 g IV associated with NNT of 22 to prevent death and NNT of 4 to prevent infection. 

Albumin also useful in patients meeting certain criteria (Cr 1.5, BUN > 30, bilirubin > 4)

Consider NG tube placement for stomach decompression (Whether placement of a nasogastric tube can help prevent aspiration has not been well studied)

Beware of renal failure and encephalopathy, which are further complications.

 

References: EMCrit, EMDoc, UpToDate








POTD: Blood Transfusions in Immunocompromised Patients

You have a chemo patient who’s been feeling weak and was sent by their oncologist to the ED for further evaluation. They look pale, maybe a little tachy, but otherwise stable. A preliminary VBG comes back with a Hct of 10%…what do you do?

Let’s talk about blood transfusions in the immunocompromised patient! Shout out to Dr. Allie Kornblatt for the clinical question!

Irradiation

What is irradiation?

Process to inactivate lymphocytes in the RBC product. 

Why is it important?

Viable donor lymphocytes can attack recipient cells in individuals who are unable to mount an immune response against them, causing transfusion-associated graft-versus-host disease (ta-GVHD). Ta-GVHD can target all hematopoietic cells as well as other tissues, leading to bone marrow aplasia and other complications that are ultimately fatal.

Who should get irradiated blood?

  • Recipients of intrauterine or neonatal exchange transfusionpremature neonates

  • Individuals with congenital cell-mediated immunodeficiency states

  • Individuals treated with specific types of potent immunosuppressive therapies (purine analogs, antithymocyte globulin [ATG], certain monoclonal antibodies); this may include those being treated for non-Hodgkin lymphoma (NHL) or other hematologic malignancies

  • Recipients of hematopoietic stem cell transplant (autologous or allogeneic)

  • Individuals with Hodgkin lymphoma (any stage of disease)

  • Individuals at risk for partial HLA matching with the donor due to directed donations, HLA-matched products, or genetically homogeneous populations

Additional Considerations

Blood ultimately has a reduced shelf life and may have a delay in arriving to the patient for transfusion.


Leukoreduction

What is leukoreduction?

Removal of leukocytes from the red cell product.

Why is it important?

These cells are present due to co-purification and do not provide any known benefit to the recipient and can potentially cause immunological mediated effects, infectious disease transmission, and repercussion injury. Some countries require universal leukoreduction of cellular blood components (RBCs and platelets), but this is not mandatory in the United States.

Who should get leukoreduced blood?

  • If cost wasn’t a factor, EVERYONE should get leukoreduced blood!

  • Patient’s that suffer from frequent febrile nonhemolytic transfusion reactions, especially if fever in these patients (e.g. immunocomprised) necessitates inpatient evaluation for occult infection

  • Patient’s awaiting organ or bone marrow transplantation and have a history of platelet refractoriness caused by Human leukocyte antigen (HLA) alloimmunization

  • Decrease the risk of postoperative infection and occult bacterial contamination

  • Patient’s with cardiac injury to prevent reperfusion injury

Additional Considerations

They have no role in preventing ta-GVHD.

CMV-Seronegative Red Cells

What are they?

RBC components that test negative for the presence of CMV using serologic methods (antibody testing).

Why is it important?

Certain immunocompromised individuals who are themselves CMV-negative may be at risk for serious infection if they receive a CMV-positive unit of blood. 

Who should get CMV-seronegative blood?

  • Solid organ transplant recipients

  • Hematopoietic stem cell transplant (HCT) recipients

  • Low birth weight neonates

  • Individuals infected with HIV

  • Pregnant women

References

https://www.uptodate.com/contents/practical-aspects-of-red-blood-cell-transfusion-in-adults-storage-processing-modifications-and-infusion?search=irradiated%20blood%20products&sectionRank=1&usage_type=default&anchor=H15&source=machineLearning&selectedTitle=1~150&display_rank=1#H2822609644

 · 

WILMS TUMOR

WILMS TUMORMost common renal malignancy in children <15yomedian age at diagnosis: 43 months in girls and 37 months in boys

ASSOCIATED WITH- AniridiaGenitourinary abnormalities- Loss of function mutations of tumor suppressor and transcription genes

CLINICAL PRESENTATIONMost common: Asymptomatic abdominal mass or swelling (typically found by parents while bathing child)- Abdominal pain (30-40%)- Hematuria (12-25%)- Hypertension (25%)

PHYSICAL EXAMCareful!!! Vigorous palpation may rupture the renal capsule, resulting in tumor spillage, increasing the tumor stage and the need for more intensive therapy- firm, non-tender, smooth mass- eccentrically located - rarely crosses the midline

DIAGNOSIS1.      Abdominal ultrasound with evaluation of mass (assess flow)2.      CT/MRI abdomen can be used to further evaluate the lesion3.      Routine CT chest - Lung is the most common metastatic site4.      Definitive: biopsy with histologic confirmation

STAGINGBased on anatomic extent of tumor

MANAGEMENTRefer to a pediatric cancer centerTypically multimodal therapy involving chemotherapy, radiation therapy and surgery    -Surgical excision for respectable tumors    -Chemotherapy for all patients except extremely low risk    -Radiation therapy indicated by stage and histology

Overall five-year survival for Wilms tumor is 90%

 ·